Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study

Blood (2024) 144 (Supplement 1): 2817.

https://doi.org/10.1182/blood-2024-211231

Published: 2024

Journal Articles

Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry

Daniel J. Landsburg, Richard T. Maziarz, Amy Moskop, Leslie L. Popplewell, Scott R. Solomon, Michael T. Tees, Yongzi Yu, Aiesha Zia, Stephen Lim, Avishek Pal, Pei Hsu, Frederick Locke

Blood (2024) 144 (Supplement 1): 4398.

https://doi.org/10.1182/blood-2024-204207

Published: 2024

Journal Articles

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Jiasheng Wang, Shakthi Bhaskar, Babatunde Adedokun, Olalekan O. Oluwole, Leland Metheny, Amy Moskop, Caron A. Jacobson, Geoffrey Shouse, Sairah Ahmed, Armin Ghobadi, Saurabh Dahiya, Jiali Yan, Zhen-Huan Hu, Timothy Best, Jenny J. Kim, Debbie L. Mirjah, Marcelo C. Pasquini, Frederick L. Locke

Blood (2024) 144 (Supplement 1): 527.

https://doi.org/10.1182/blood-2024-209093

Published: 2024

Journal Articles

Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Christopher Strouse, Umar Farooq, Roni Shouval, Anusha Vallurupalli, Amy Moskop, Caron A. Jacobson, Frederick Locke, John H. Baird, Paolo Strati, Dilan A. Patel, Saurabh Dahiya, Michael T. Hemmer, Brad Du, Clare Spooner, Jenny J. Kim, Debbie L. Mirjah, Zhen-Huan Hu, Marcelo C. Pasquini, Yi Lin

Blood (2024) 144 (Supplement 1): 609.

https://doi.org/10.1182/blood-2024-207976

Published: 2024

Journal Articles

Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Alaa Ali, Nausheen Ahmed, Soyoung Kim, Matthew Bye, Sayeef Mirza, Alex Gordon Sieg, Christopher Strouse, Kalyan Nadiminti, Priyanka A. Pophali, Rammurti T. Kamble, Lohith Gowda, Cameron J. Turtle, Christine L. Phillips, Marcelo C. Pasquini, Sairah Ahmed, Siddhartha Ganguly, Amy Moskop

Blood (2024) 144 (Supplement 1): 71.

https://doi.org/10.1182/blood-2024-200269

Published: 2024

Journal Articles

Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 2133.

https://doi.org/10.1182/blood-2023-189921

Published: 2023

Journal Articles

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Daniel J. Landsburg, Michael Heim, Amy Moskop, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini, Matthew J Frigault

Blood (2023) 142 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2023-179387

Published: 2023

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Journal Articles

Establishing Costs for Commercial Chimeric Antigen Receptor T-Cell (Tisagenlecleucel; Kymriah) in Children and Young Adult B-Cell Acute Lymphoblastic Leukemia; A Merged Analysis from the Prwcc and PHIS

Blood (2023) 142 (Supplement 1): 6912.

https://doi.org/10.1182/blood-2023-187462

Published: 2023

Journal Articles

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Blood (2022) 140 (Supplement 1): 4636–4638.

https://doi.org/10.1182/blood-2022-169452

Published: 2022

Journal Articles

Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)

Abu-Sayeef Mirza, Chitra Hosing, Francine M. Foss, Soyoung Kim, Amy Moskop, Temitope Oloyede, Sairah Ahmed, Peiman Hematti, Cameron J. Turtle, Marcelo C. Pasquini, Lohith Gowda

Blood (2022) 140 (Supplement 1): 4633–4635.

https://doi.org/10.1182/blood-2022-163750

Published: 2022

Journal Articles

Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel

Blood (2022) 140 (Supplement 1): 10419–10421.

https://doi.org/10.1182/blood-2022-163336

Published: 2022

Journal Articles

Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups

Blood (2022) 140 (Supplement 1): 10386–10388.

https://doi.org/10.1182/blood-2022-165951

Published: 2022

Journal Articles

Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults

Blood (2022) 140 (Supplement 1): 4661–4663.

https://doi.org/10.1182/blood-2022-169603

Published: 2022

Journal Articles

Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

Blood (2021) 138 (21): 2138–2142.

https://doi.org/10.1182/blood.2021012392

Published: 2021

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)

Blood (2021) 138 (Supplement 1): 3880.

https://doi.org/10.1182/blood-2021-148652

Published: 2021

Journal Articles

Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Samuel John, Michael A. Pulsipher, Amy Moskop, Zhen-Huan Hu, Christine L. Phillips, Erin Marie Hall, Steven P. Margossian, Sarah Nikiforow, Paul L. Martin, Benjamin Oshrine, Amy K. Keating, Rayne H. Rouce, Ranjan Tiwari, Santiago Redondo, Jennifer Willert, Abhijit Agarwal, Marcelo C Pasquini, Stephan A. Grupp

Blood (2021) 138 (Supplement 1): 428.

https://doi.org/10.1182/blood-2021-146393

Published: 2021

Journal Articles

Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-134472

Published: 2020

Journal Articles

Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-136674

Published: 2020

Journal Articles

Comparison of Health Outcomes in Adolescent and Young Adults (AYA) Oncology Patients Treated at a Pediatric Versus Adult Institute

Amy Moskop, MD, Ke Yan, PhD, Sarah K. Dobrozsi, MD, Julie Panepinto, MDMSPH

Blood (2019) 134 (Supplement_1): 4743.

https://doi.org/10.1182/blood-2019-121616

Published: 2019

NARROW

Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study

Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Establishing Costs for Commercial Chimeric Antigen Receptor T-Cell (Tisagenlecleucel; Kymriah) in Children and Young Adult B-Cell Acute Lymphoblastic Leukemia; A Merged Analysis from the Prwcc and PHIS

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)

Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel

Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups

Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults

Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)

Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)

Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release

Comparison of Health Outcomes in Adolescent and Young Adults (AYA) Oncology Patients Treated at a Pediatric Versus Adult Institute

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only